Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia

@article{Mantovani2009PhaseIN,
  title={Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia},
  author={Giovanni Mantovani and Antonio Macci{\`o} and Clelia Madeddu and Roberto Serpe and Giorgia Antoni and E. Rabino Massa and M. Dessi and Filomena Panzone},
  journal={Journal of Molecular Medicine},
  year={2009},
  volume={88},
  pages={85-92}
}
Chronic inflammation is one of the main features of cancer cachexia. Experimental and clinical studies showed that cyclooxygenase-2 inhibitors, such as celecoxib, may be beneficial in counteracting major symptoms of this devastating syndrome. We carried out a prospective phase II clinical trial to test the safety and effectiveness of an intervention with the COX-2 inhibitor celecoxib (300 mg/day for 4 months) on key variables of cachexia (lean body mass, resting energy expenditure, serum levels… CONTINUE READING